Capital Impact Advisors LLC Reduces Position in PAREXEL International Corporation (NASDAQ:PRXL)

Capital Impact Advisors LLC lowered its position in PAREXEL International Corporation (NASDAQ:PRXL) by 27.7% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 17,269 shares of the medical research company’s stock after selling 6,615 shares during the period. Capital Impact Advisors LLC’s holdings in PAREXEL International Corporation were worth $1,501,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of the company. Capstone Asset Management Co. raised its position in shares of PAREXEL International Corporation by 3.8% in the first quarter. Capstone Asset Management Co. now owns 4,409 shares of the medical research company’s stock worth $278,000 after buying an additional 160 shares in the last quarter. Clinton Group Inc. acquired a new position in shares of PAREXEL International Corporation during the first quarter worth $3,682,000. Legato Capital Management LLC raised its position in shares of PAREXEL International Corporation by 6,211.0% in the first quarter. Legato Capital Management LLC now owns 92,393 shares of the medical research company’s stock worth $1,464,000 after buying an additional 90,929 shares in the last quarter. Macquarie Group Ltd. acquired a new position in shares of PAREXEL International Corporation during the fourth quarter worth $789,000. Finally, LSV Asset Management raised its position in shares of PAREXEL International Corporation by 43.9% in the first quarter. LSV Asset Management now owns 380,751 shares of the medical research company’s stock worth $24,029,000 after buying an additional 116,200 shares in the last quarter. Institutional investors and hedge funds own 93.48% of the company’s stock.

Shares of PAREXEL International Corporation (PRXL) traded down 0.03% during midday trading on Friday, reaching $87.62. 555,915 shares of the company were exchanged. The company has a 50 day moving average price of $87.32 and a 200-day moving average price of $73.97. The stock has a market capitalization of $4.45 billion, a P/E ratio of 38.51 and a beta of 0.79. PAREXEL International Corporation has a 12-month low of $51.16 and a 12-month high of $87.86.

TRADEMARK VIOLATION WARNING: “Capital Impact Advisors LLC Reduces Position in PAREXEL International Corporation (NASDAQ:PRXL)” was reported by BNB Daily and is owned by of BNB Daily. If you are reading this article on another domain, it was stolen and reposted in violation of United States and international trademark & copyright laws. The correct version of this article can be read at https://www.baseball-news-blog.com/2017/08/13/capital-impact-advisors-llc-decreases-stake-in-parexel-international-corporation-nasdaqprxl-updated-updated-updated.html.

A number of equities analysts have weighed in on PRXL shares. BidaskClub lowered shares of PAREXEL International Corporation from a “strong-buy” rating to a “buy” rating in a research report on Friday, July 28th. Mizuho increased their target price on shares of PAREXEL International Corporation from $66.00 to $75.00 and gave the stock a “buy” rating in a research report on Tuesday, May 30th. Barclays PLC reiterated an “overweight” rating and set a $87.00 target price on shares of PAREXEL International Corporation in a research report on Wednesday, May 17th. Evercore ISI upgraded shares of PAREXEL International Corporation from an “in-line” rating to an “outperform” rating and set a $85.00 target price for the company in a research report on Monday, May 15th. Finally, Zacks Investment Research upgraded shares of PAREXEL International Corporation from a “hold” rating to a “buy” rating and set a $98.00 target price for the company in a research report on Tuesday, August 8th. Two investment analysts have rated the stock with a sell rating, nine have issued a hold rating and four have given a buy rating to the company’s stock. PAREXEL International Corporation presently has an average rating of “Hold” and a consensus target price of $75.93.

PAREXEL International Corporation Company Profile

PAREXEL International Corporation (PAREXEL) is a biopharmaceutical outsourcing services company. The Company provides a range of expertise in clinical research, clinical logistics, medical communications, consulting, commercialization, and technology products and services to pharmaceutical, biotechnology and medical device industries.

Institutional Ownership by Quarter for PAREXEL International Corporation (NASDAQ:PRXL)

Receive News & Ratings for PAREXEL International Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PAREXEL International Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply